96 related articles for article (PubMed ID: 26053896)
1. Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur.
Wernham AG; Shah F; Amel-Kashipaz R; Cobbold M; Scarisbrick J
Br J Dermatol; 2015 Nov; 173(5):1295-7. PubMed ID: 26053896
[No Abstract] [Full Text] [Related]
2. The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients.
Sanz-Bueno J; Lora D; Monsálvez V; Maroñas-Jiménez L; Postigo C; Rodríguez-Peralto JL; Ortiz-Romero PL
Br J Dermatol; 2016 Oct; 175(4):794-6. PubMed ID: 26990536
[No Abstract] [Full Text] [Related]
3. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
4. Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome.
Evans KG; Troxel AB; DeNardo BJ; Introcaso CE; Rook AH; Kim EJ
J Am Acad Dermatol; 2011 Apr; 64(4):682-9. PubMed ID: 21315479
[TBL] [Abstract][Full Text] [Related]
5. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas.
Quaglino P; Pimpinelli N; Berti E; Calzavara-Pinton P; Alfonso Lombardo G; Rupoli S; Alaibac M; Bottoni U; Carbone A; Fava P; Fimiani M; Mamusa AM; Titli S; Zinzani PL; Bernengo MG;
Cancer; 2012 Dec; 118(23):5830-9. PubMed ID: 22674564
[TBL] [Abstract][Full Text] [Related]
6. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of tumour development correlates with prognosis in tumour stage (stage IIB) mycosis fungoides.
Boonk SE; Putter H; Koolhof L; Willemze R; Vermeer MH
Br J Dermatol; 2014 May; 170(5):1080-6. PubMed ID: 24299563
[TBL] [Abstract][Full Text] [Related]
9. Early-stage Mycosis Fungoides: Epidemiology and Prognosis.
Maguire A; Puelles J; Raboisson P; Chavda R; Gabriel S; Thornton S
Acta Derm Venereol; 2020 Jan; 100(1):adv00013. PubMed ID: 31663598
[TBL] [Abstract][Full Text] [Related]
10. Minimal stage IA mycosis fungoides. Results of radiotherapy in 15 patients.
Piccinno R; Caccialanza M; Percivalle S
J Dermatolog Treat; 2009; 20(3):165-8. PubMed ID: 18979277
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
12. A high expression of cell adhesion molecule 1 (CADM1) is an unfavorable prognostic factor in mycosis fungoides.
Mashima E; Sawada Y; Yamaguchi T; Yoshioka H; Ohmori S; Haruyama S; Yoshioka M; Okada E; Nakamura M
Clin Immunol; 2018 Aug; 193():121-122. PubMed ID: 29391198
[No Abstract] [Full Text] [Related]
13. Mycosis fungoides and follicular mucinosis.
Vollmer RT
Arch Dermatol; 2002 Dec; 138(12):1613-4; author reply 1614-5. PubMed ID: 12472358
[No Abstract] [Full Text] [Related]
14. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
15. Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: a Danish nationwide, population-based cohort study.
Lindahl LM; Fenger-Grøn M; Iversen L
J Am Acad Dermatol; 2014 Sep; 71(3):529-35. PubMed ID: 24836079
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
[TBL] [Abstract][Full Text] [Related]
17. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States.
Jones GW; Wilson LD
Cancer; 1999 Jul; 86(1):191-3. PubMed ID: 10391580
[No Abstract] [Full Text] [Related]
18. Total skin electron beam therapy in mycosis fungoides. Our experience from 1985 to 1999.
Rampino M; Ragona R; Monetti U; Mussano A; Guarneri A; Sannazzari GL
Radiol Med; 2002; 103(1-2):108-14. PubMed ID: 11859306
[TBL] [Abstract][Full Text] [Related]
19. [Clinical course and treatment of mycosis fungoides].
Laczkowska M
Pol Tyg Lek; 1988 Feb; 43(5):131-5. PubMed ID: 3405881
[No Abstract] [Full Text] [Related]
20. A review of survival in mycosis fungoides.
Vollmer RT
Am J Clin Pathol; 2014 May; 141(5):706-11. PubMed ID: 24713743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
